Peer Reviewed
Finerenone emerges as a promising treatment for patients with diabetes and chronic kidney disease, significantly reducing cardiovascular and renal risks.
Andy Dang, PharmD Candidate
Advertisement
Andy Dang is a PharmD candidate at the University of Houston College of Pharmacy in Texas.
Articles by Andy Dang, PharmD Candidate
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
3
Why Some Patients Do Not Respond to GLP-1 Therapies
4
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
5